白皮书

New Product Alert - Ripretinib

Ripretinib works by binding to two key regions of the kinase (the switch pocket and activation loop), locking it in an inactive state. This prevents the kinase from promoting abnormal cell growth, effectively inhibiting a wide range of mutations in KIT and PDGFRA kinases.

Our Offerings*:

• Offers stable crystalline Form 1.
• US & Brazil DMFs filed.
• Our current batch size is 8 Kg (Crystalline) and planning adequate capacity with a short lead time of 90 days.
• Regulatory compliance and quality ensure our API is genotoxic and nitrosamine-free, adhering to ICH M7 guidelines.
• We offer immediate samples with CoA and impurity profiles, allowing you to evaluate our API's quality and suitability.

To learn more about our API offerings, please read the Product alert on Ripretinib by filling out the contact form below.